Although severe irCAEs (grade ≥ 3) occurred in only a few PD-1/PD-L1 checkpoint inhibitor-treated patients with tumours, they had a significant impact on patients, especially their health-related quality of life. This evidence concerns the gene PDCD1 and neoplasm.